Live WebinarDemystifying the use of allograft bone cylinders in your practice
08 Apr 2020, 01:00 AM Berlin
Robert Miller DMD
The new implant surface is based on SurfLink technology, which was developed over a period of 12 years by Swiss company NBMolecules in collaboration with various academic institutions in Switzerland. It consists of a permanently bound layer of hydrophilic phosphorous-rich molecules applied to the implant surface, can be used with metallic or ceramic dental and orthopaedic implants, and offers a range of benefits not found with any other surface treatment currently available.
In Barcelona, Dr Björn-Owe Aronsson, Executive Director and Chief Technology Officer at NBMolecules, introduced SurfLink to conference participants. He concluded that SurfLink is a unique bio-mimicking implant surface treatment resulting in a bone-like surface. Its unique properties make the implant hydrophilic, allowing for a new type of integration by eliminating the micro-gap between the bone and the implant, and enhance fixation at an early stage for long-term stability. Thus, the implant surface helps produce predictable results in challenging cases, such as patients with compromised bone healing and poor blood supply.
In addition, Dr Marco Esposito, Associate Professor of Biomaterials at the Sahlgrenska Academy of the University of Gothenburg in Sweden, presented the first clinical data on the new implant surface. Results from preliminary studies have shown that B+ is clinically safe, he stated. In order to verify the findings in larger cohorts, several universities are currently conducting tests in humans, with over 100 participants.
At a press meeting during the conference, Doron Peretz, Senior Vice President of Marketing and Development at MIS, explained that, together with the V3 Implant System with its unique triangular shape for enhanced hard- and soft-tissue regeneration around the implant, the B+ implant surface is the only real innovation in the dental implant market in the last several years and thus positions MIS as the leader in the value segment.
In an on-site interview with Dental Tribune Online, Prof. Mariano Sanz from the Complutense University of Madrid in Spain, said: “The implications of the B+ are very interesting. The preliminary results that were presented at this conference show that the B+ helps create a very stable interface. Reaching osseointegration is important and can be achieved through many implant surface treatments today. However, maintaining osseointegration is the most crucial aspect of dental implantology. If the B+ proves to do exactly this in the ongoing studies, then I believe it will be a great innovation.”
The B+ will become available in March next year after the International Dental Show in Cologne in Germany. Sales of the V3 implant system started in the last quarter of 2015 in eight countries. To date MIS has sold about 20,000 of these implants.